title: Her-2/neu oncogene amplification in clinically localised prostate cancer.
abstract: OBJECTIVE
  To examine the incidence of Her-2/neu oncogene amplification in clinically localised prostate cancer using in situ hybridisation.
  
  
  METHODS
  One hundred and seventeen patients, who had undergone radical prostatectomy, were identified and in situ hybridisation was performed on formalin fixed, paraffin wax embedded tissue using the Quantum Appligene probe for Her-2/neu. The enzyme peroxidase was used to detect the probe because this enabled a permanent record to be kept. Tumours in which there were five or more signals in each nucleus in > 20% of the tumour cells were considered to have a significantly increased copy number. A serial section from these tumours was then hybridised with the chromosome 17 alpha satellite probe. The ratio of the percentage of cells showing an increase in Her-2/neu copy number to the number showing polysomy for chromosome 17 was calculated. A ratio above 2 was considered amplified.
  
  
  RESULTS
  Biochemical recurrence occurred in 50 (43%) patients and 24 (21%) had clinical recurrence. In situ hybridisation for Her-2/neu was accessible in 114 (97%) patients. A significant increase in copy number was present in two patients (1.75 %), but chromosome 17 hybridisation showed that the increase was the result of polysomy rather than true amplification. Both these patients had a Gleason score of 7 and stage T3; they also had recurrent clinical disease with distal metastasis within two and 19 months.
  
  
  CONCLUSIONS
  Increased Her-2/neu oncogene copy number appears to be rare in clinically localised prostatic adenocarcinoma and is related to chromosome 17 polysomy rather than true amplification. As a result, it would not be a useful biomarker for identifying those patients who will have recurrences after radical prostatectomy.
authors.affiliation: Department of Cellular Pathology, Southmead Hospital, Westbury on Trym, Bristol BS10 5NB, UK. jon@jon-oxley.freeserve.co.uk
authors.forename: J D
authors.initials: JD
authors.lastname: Oxley
authors.forename: M H
authors.initials: MH
authors.lastname: Winkler
authors.forename: D A
authors.initials: DA
authors.lastname: Gillatt
authors.forename: D S
authors.initials: DS
authors.lastname: Peat
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D000368:Aged; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D005500:Follow-Up Studies; D005784:Gene Amplification; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D012008:Recurrence